{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:24:19Z","timestamp":1740126259436,"version":"3.37.3"},"reference-count":9,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Merck-Sharp Dome"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Raltegravir is used in many antiretroviral combinations, but its use in treatment\u2010experienced patients without knowledge of baseline resistance is discussed controversially as a number of comparative studies have shown a higher rate of virological failure. However, it has been used frequently for the management of treatment failure, as it was the first integrase inhibitor to become available, and thus offered new options for patients with multiple resistance. The strategic use of raltegravir in this setting is examined in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In order to examine the efficacy of raltegravir in second and later lines of antiretroviral combinations, data for 740 patients from three clinical cohorts were analysed with a focus on the combinations that were used. These were stratified into the combination of two nonnucleoside reverse transcriptase inhibitors and raltegravir (2<jats:styled-content style=\"fixed-case\">NRTI<\/jats:styled-content>s + <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>), the combination of a boosted protease inhibitor and raltegravir (<jats:styled-content style=\"fixed-case\">bPI<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>), and other raltegravir\u2010containing combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall rate of virological suppression to &lt; 50 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> copies\/mL was 69.5%. Although the baseline rate of virological suppression was higher for 2<jats:styled-content style=\"fixed-case\">NRTI<\/jats:styled-content>s + <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content> than for the other strata, the outcomes were similar for all three groups at weeks 24, 48, 72 and 96.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data indicate that, in a real\u2010life setting, raltegravir can be used with a high virological success rate in treatment\u2010experienced patients, and that the different combinations analysed (2<jats:styled-content style=\"fixed-case\">NRTI<\/jats:styled-content>s + <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> bPI<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">RAL<\/jats:styled-content> and others) show comparable rates of virological suppression.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12636","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T03:33:27Z","timestamp":1530675207000},"page":"662-667","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Similar long\u2010term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV\u20101\u2010infected patients in a retrospective, real\u2010life cohort of 14 years"],"prefix":"10.1111","volume":"19","author":[{"given":"I","family":"Krznaric","sequence":"first","affiliation":[{"name":"Centre for Infectious Diseases Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bickel","sequence":"additional","affiliation":[{"name":"Infektiologikum (Centre for Infectious Diseases) Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carganico","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"De Leuw","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Internal Medicine II HIV Center University Hospital Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Haberl","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Internal Medicine II HIV Center University Hospital Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Knecht","sequence":"additional","affiliation":[{"name":"Infektiologikum (Centre for Infectious Diseases) Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Koegl","sequence":"additional","affiliation":[{"name":"MUC Research Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lauscher","sequence":"additional","affiliation":[{"name":"MUC Research Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sch\u00fcttfort","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Internal Medicine II HIV Center University Hospital Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Stephan","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Internal Medicine II HIV Center University Hospital Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Wolf","sequence":"additional","affiliation":[{"name":"MUC Research Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-9540","authenticated-orcid":false,"given":"T","family":"Wolf","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Department of Internal Medicine II HIV Center University Hospital Frankfurt Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70093-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr269"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416679550"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2812"},{"key":"e_1_2_6_7_1","unstructured":"EACS (European AIDS Clinical Society) Guidelines Version 9.0 October2017. Available athttp:\/\/www.eacsociety.org(accessed 11 November 2017)."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv427"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30630-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1018-z"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T01:14:12Z","timestamp":1694999652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/hiv.12636"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12636","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"2018-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}